Cargando…

Vx-809, a CFTR Corrector, Acts through a General Mechanism of Protein Folding and on the Inflammatory Process

Correct protein folding is the basis of cellular well-being; thus, accumulation of misfolded proteins within the endoplasmic reticulum (ER) leads to an imbalance of homeostasis that causes stress to the ER. Various studies have shown that protein misfolding is a significant factor in the etiology of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pecoraro, Michela, Serra, Adele, Pascale, Maria, Franceschelli, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965627/ https://www.ncbi.nlm.nih.gov/pubmed/36835664 http://dx.doi.org/10.3390/ijms24044252

Ejemplares similares

Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays
por: Parodi, Alice, et al.
Publicado: (2022)

CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium
por: Braccia, Clarissa, et al.
Publicado: (2022)

Matrine in association with FD-2 stimulates F508del-cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809
por: Marengo, Barbara, et al.
Publicado: (2017)

Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
por: Stanton, Bruce A., et al.
Publicado: (2015)

Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR
por: Farinha, Carlos M, et al.
Publicado: (2015)

Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis
por: Pecoraro, Michela, et al.
Publicado: (2021)

Folding correctors can restore CFTR posttranslational folding landscape by allosteric domain–domain coupling
por: Soya, Naoto, et al.
Publicado: (2023)

VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
por: Ren, Hong Yu, et al.
Publicado: (2013)

Pharmacological Correctors of Mutant CFTR Mistrafficking
por: Pedemonte, Nicoletta, et al.
Publicado: (2012)

High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue
por: Perkins, Lydia A., et al.
Publicado: (2018)

Small molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states
por: Riepe, Celeste, et al.
Publicado: (2023)

Repairing folding-defective α-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D
por: Carotti, Marcello, et al.
Publicado: (2018)

Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors
por: Saint-Criq, Vinciane, et al.
Publicado: (2021)

Bithiazole Correctors Rescue CFTR Mutants by Two Different Mechanisms
por: Loo, Tip W., et al.
Publicado: (2013)

Correctors modify the bicarbonate permeability of F508del-CFTR
por: Fiore, Michele, et al.
Publicado: (2020)

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
por: Spanò, Virginia, et al.
Publicado: (2021)

CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3
por: Scano, Martina, et al.
Publicado: (2021)

Therapeutic Potential for CFTR Correctors in Autosomal Recessive Polycystic Kidney Disease
por: Yanda, Murali K., et al.
Publicado: (2021)

Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery
por: Carotti, Marcello, et al.
Publicado: (2020)

Functional Rescue of F508del-CFTR Using Small Molecule Correctors
por: Molinski, Steven, et al.
Publicado: (2012)

Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine
por: Matthes, Elizabeth, et al.
Publicado: (2018)

Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis
por: Lopes-Pacheco, Miquéias, et al.
Publicado: (2017)

Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel
por: Pedemonte, Nicoletta, et al.
Publicado: (2020)

Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs
por: Abu-Arish, Asmahan, et al.
Publicado: (2022)

Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel
por: Renda, Mario, et al.
Publicado: (2023)

Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs
por: Lester, Anna, et al.
Publicado: (2023)

Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
por: Yeh, Han-I, et al.
Publicado: (2019)

CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells
por: Veltman, Mieke, et al.
Publicado: (2021)

Constrained Bithiazoles: Small Molecule Correctors of Defective ΔF508–CFTR Protein Trafficking
por: Coffman, Keith C., et al.
Publicado: (2014)

Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain
por: Odolczyk, Norbert, et al.
Publicado: (2013)

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
por: Capurro, Valeria, et al.
Publicado: (2021)

VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level
por: Cui, Guiying, et al.
Publicado: (2019)

Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination
por: Kleinfelder, Karina, et al.
Publicado: (2023)

Mechanisms of CFTR Folding at the Endoplasmic Reticulum
por: Kim, Soo Jung, et al.
Publicado: (2012)

Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
por: Matos, Ana M., et al.
Publicado: (2021)

Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation
por: Rapino, Daniele, et al.
Publicado: (2015)

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
por: Righetti, Giada, et al.
Publicado: (2020)

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
por: Amico, Giulia, et al.
Publicado: (2019)

Trastuzumab and Doxorubicin Sequential Administration Increases Oxidative Stress and Phosphorylation of Connexin 43 on Ser368
por: Pecoraro, Michela, et al.
Publicado: (2022)

Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators
por: de Wilde, Gert, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_buh534ls50sa5134b7i2ejagtc